ERBB2 and breast carcinoma: Subsequently, we assessed the impact of this microRNA target, SEMA6D, on patient outcomes, specifically after chemotherapy, in a cohort containing all the diversity of breast cancer subtypes that are treated with chemotherapy, demonstrating its applicability to this treatment modality beyond the estrogen receptor positive/HER2 negative subtype used for discovery.